rurioctocog alfa pegol
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Jul 15, 2019 (NCT04015492)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- Coagulation factor VIIISupplementation
F8 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- rurioctocog alfa pegol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05036278 | Phase 4 | Nov 22, 2021 | Bayer |
| NCT05042440 | Phase 1 | Aug 11, 2021 | Sanofi |
| NCT04015492 | Phase 1 | Jul 15, 2019 | Bayer |
Showing 3 of 3 trials
Page 1 / 1